This clinical trial is focused on patients who are undergoing a planned hip replacement surgery, known as hip arthroplasty. The study is examining the use of a medication called Rivaroxaban, which is a type of blood thinner, to prevent blood clots after surgery. Blood clots can lead to serious conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE). The trial will compare a shorter treatment period of 10 days with the usual 35-day treatment to see if the shorter period is just as effective in preventing these complications.

Participants in the study will receive either the medication Rivaroxaban or a placebo, which looks like the medication but does not contain the active ingredient. The study aims to find out if the shorter duration of taking Rivaroxaban is as safe and effective as the longer duration. The trial will monitor for any signs of blood clots, as well as other health outcomes such as overall recovery, any serious side effects, and the need for additional hospital visits.

The study will follow participants for up to 90 days after they join to track their recovery and any health issues that arise. This research is important to potentially reduce the length of time patients need to take blood thinners after hip surgery, which could lead to fewer side effects and a quicker return to normal activities.